Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: NutraMax

This article was originally published in The Tan Sheet

Executive Summary

NutraMax: Sales increased 56.4% to $34.5 mil. for the fiscal first quarter ended Jan. 3, boosted by the recently acquired first aid line, which contributed nearly 25% of total sales for the three months. Sales for cough/cold products rose 27% during the quarter and accounted for 33% of net sales. Net income for the quarter fell 47.4% to $810,000, as the company continues to feel the effects of start-up problems associated with its new production capacity. Commenting on results, the Gloucester, Mass.-based company said "customer orders remain strong and our single most important challenge remains the reduction of our order backlog." Shipments from the company's new national distribution center began in early January and the facility was expected to be fully functional by the end of January...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel